U.S. patent number 3,896,119 [Application Number 05/292,798] was granted by the patent office on 1975-07-22 for xanthines substituted in the 8-position.
This patent grant is currently assigned to Deutsche Gold- und Silber-Scheideanstalt vormals Roessler. Invention is credited to Karl-Heinz Klingler.
United States Patent |
3,896,119 |
Klingler |
July 22, 1975 |
Xanthines substituted in the 8-position
Abstract
Compound are prepared having the formula: ##EQU1## where R.sub.1
is hydrogen or methyl, R.sub.2 and R.sub.3 are hydrogen, methyl,
hydroxy, or hydroxymethyl, R.sub.7 is hydrogen or methyl and
R.sub.4 is alkyl of 1 to 6 carbon atoms, phenylalkyl of 7 to 12
carbon atoms or --NR.sub.5 R.sub.6 where R.sub.5 and R.sub.6
individually are hydrogen or alkyl of 1 to 6 carbon atoms or
R.sub.5 and R.sub.6 together with the nitrogen atom form a 5 to 7
membered ring which can have an additional oxygen, nitrogen or
sulfur atom and also can contain 0 to 2 alkyl substituents with 1
to 4 carbon atoms or salts thereof. The compounds have outstanding
broncholytic activity.
Inventors: |
Klingler; Karl-Heinz (Langen,
DT) |
Assignee: |
Deutsche Gold- und
Silber-Scheideanstalt vormals Roessler (DT)
|
Family
ID: |
3613058 |
Appl.
No.: |
05/292,798 |
Filed: |
September 27, 1972 |
Foreign Application Priority Data
|
|
|
|
|
Oct 28, 1971 [OE] |
|
|
9312/71 |
|
Current U.S.
Class: |
544/118; 514/826;
540/544; 540/553; 540/575; 540/600; 544/3; 544/61; 544/272 |
Current CPC
Class: |
Y10S
514/826 (20130101) |
Current International
Class: |
C07D
473/04 (20060101); C07d 087/34 () |
Field of
Search: |
;260/247.2,256,243B,239BC |
Other References
kubotz et al., Pharmaceutical Society of Japan, Vol. 89, pp.
441-444, 1969..
|
Primary Examiner: Gerstl; Robert
Assistant Examiner: Killos; Paul J.
Attorney, Agent or Firm: Cushman, Darby & Cushman
Claims
What is claimed is:
1. A compound having the formula: ##EQU13## wherein R.sub.1 is
hydrogen or methyl, R.sub.2 and R.sub.3 are hydrogen, methyl,
hydroxy or hydroxymethyl, R.sub.7 is hydrogen or methyl and R.sub.4
is ##EQU14## where R.sub.5 and R.sub.6 individually are hydrogen or
alkyl of 1 to 6 carbon atoms or R.sub.5 and R.sub.6 collectively
together with the nitrogen atom form a 5 to 7 membered heterocyclic
ring with 0 to 1 additional hetero atom and 0 to 2 alkyl
substituents, said additional hetero atom being nitrogen, sulfur or
oxygen, or a pharmacologically acceptable salt thereof.
2. A compound according to claim 1 wherein R.sub.5 and R.sub.6 are
hydrogen or alkyl of 1 to 6 carbon atoms.
3. A compound according to claim 2 wherein R.sub.3 is hydroxyl.
4. A compound according to claim 2 wherein both R.sub.5 and R.sub.6
are alkyl of 1 to 6 carbon atoms.
5. A compound according to claim 4 wherein R.sub.3 is hydroxyl.
6. A compound according to claim 4 wherein both R.sub.5 and R.sub.6
are ethyl.
7. A compound according to claim 6 wherein R.sub.3 is
hydroxyyl.
8. A compound according to claim 1 wherein when R.sub.5 and R.sub.6
are taken collectively with the nitrogen atom the heteroCyclic ring
has the formula ##EQU15## or is methyl morpholino, where n is 1 to
3 and X is CH.sub.2, nitrogen or oxygen.
9. A compound according to claim 8 wherein R.sub.2 is hydrogen,
methyl or hydroxyl, R.sub.3 is hydroxyl, and R.sub.4 is
dialkylamino wherein the alkyl group has 1 to 6 carbon atoms,
morpholino, methylmorpholino or piperidino.
10. A compound according to claim 9 wherein R.sub.2, R.sub.3, and
R.sub.7 are in the 3, 4 and 5 positions.
11. A compound according to claim 8 wherein R.sub.2 is hydrogen,
methyl, hydroxy or hydroxymethyl, R.sub.3 is hydroxy and R.sub.2,
R.sub.3 and R.sub.7 are in the 3,4 and 5 positions, and R.sub.4 is
morpholino or methylmorpholino.
12. A compound according to claim 8 wherein R.sub.1 is hydrogen,
R.sub.2 and R.sub.3 are hydroxyl groups in the 3,4 or 3,5 position
and R.sub.4 is a ring of the formula: ##EQU16## where X is
CH.sub.2, N or O or R.sub.4 is methyl morpholino.
13. A compound according to claim 8 wherein R.sub.7 is methyl.
14. A compound according to claim 8 wherein R.sub.7 is
hydrogen.
15. A compound according to claim 14 wherein R.sub.2 is hydrogen,
methyl or hydroxyl, R.sub.3 is hydroxyl, R.sub.4 is diethylamino,
morpholino, or methyl morpholino.
16. A compound according to claim 1 wherein R.sub.4 ##EQU17## where
X is CH.sub.2, nitrogen or oxygen, n is 1 to 3 or heterocyclic ring
compounds of said formula wherein up to 2 of the hydrogen atoms are
replaced by alkyl.
17. A compound according to claim 16, wherein X is oxygen and n is
2.
18. A compound according to claim 17 wherein ##EQU18## is
morpholino or alkyl morpholino having 1 to 4 carbon atoms in the
alkyl group.
19. A compound according to claim 18 wherein ##EQU19## is
morpholino or methyl morpholino.
20. A compound according to claim 19 wherein R.sub.2 is hydrogen,
methyl or hydroxyl and R.sub.3 is hydroxyl.
21. A compound according to claim 20 wherein R.sub.2, R.sub.3 and
R.sub.7 are in the 3, 4 and 5 positions.
22. A compound according to claim 18, wherein R.sub.7 is
methyl.
23. A compound according to claim 18, wherein R.sub.7 is hydrogen.
Description
The present invention relates to compounds of the formula: ##EQU2##
where R.sub.1 is hydrogen or methyl, R.sub.2 and R.sub.3 are
hydrogen, methyl, hydroxy, or hydroxymethyl, R.sub.7 is hydrogen or
methyl and R.sub.4 is alkyl of 1 to 6 carbon atoms, phenylalkyl of
7 to 12 carbon atoms or ##EQU3## where R.sub.5 and R.sub.6
individually are hydrogen or alkyl 1 to 6 carbon atoms or R.sub.5
and R.sub.6 together with the nitrogen atom form a 5 to 7 membered
ring which can have an additional oxygen, nitrogen or sulfur atom
and also can contain up to 2 alkyl substituents with 1 to 4 carbon
atoms or acid addition salts thereof. The substituents R.sub.2 and
R.sub.3 are preferably located in the 3, 4 and 5 positions of the
phenyl nucleus. Especially favorable properties are possessed by
those compounds in which at least one of the R.sub.2 and R.sub.3
groups is a hydroxy group and the other is either hydrogen,
hydroxy, methyl or hydroxymethyl, R.sub.4 is preferably a
morpholino group or an alkyl substituted morpholino group. Also
especially suitable are those compounds in which R.sub.1 is
hydrogen, R.sub.2 and R.sub.3 are hydroxy groups in the 3, 4 or 3,
5 positions and R.sub.4 is a ring of the formula: ##EQU4## WHERE N
IS A MEMBER FROM 1 TO 3 AND X is a CH.sub.2 group or in the case n
is 2 or 3 X can also be either oxygen or nitrogen or R.sub.4 can be
a methyl substituted morpholino group.
The compounds of the invention are pharmacologically active and
especially have a strong broncholytic activity. There are also
present valuable circulatory activity.
As salts of the amines of formula I, there can be prepared and
employed salts of any non-toxic pharmacologically acceptable acids
such as hydrochloric acid, hydrobromic acid, sulfuric acid, acetic
acid, p-toluene sulfonic acid, propionic acid, succinic acid,
maleic acid, malonic acid, fumaric acid, lactic acid, tartaric acid
and citric acid.
The compounds can be converted from the salts to the free bases
again in customary manner, for example, by treating a solution in
an organic medium such as alcohols, e.g., methanol with sodium
carbonate or soda lye.
Examples of compounds within the invention in addition to those
mentioned in the specific examples include 7
-{3-[2-(3-hydroxymethyl-4-hydroxy-5-methylphenyl)-2-hydroxyethylamino]-pro
pyl} -8-dimethylamino-theophylline; 7-
{3-[2-(3,4-di(hydroxymethyl)-phenyl)-2-hydroxyethylamino]-propyl}
-8-morpholinotheophylline; 7- {3-[2-(4-hydroxymethyl
phenyl)-1-methyl-2-hydroxyethylamino]-propyl} -8-methyl
aminotheophylline; 7-{3-[
2-(phenyl)-2-hydroxyethylamino]-propyl}-8-(2,6-dimethyl)
morpholino-theophylline;
7-.ltorsim.3-[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl-amino]-propyl}-8-amin
o-theophylline;
7-{3-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl-amino]-propyl}-8-hexylaminoth
eophylline;
7-{3-[2-(3,4-dihydroxyphenyl)-2-hydroxyethylamino]-propyl}-8-hexylamino-th
eophylline;
7-{3-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl-amino]-propyl-}-8-di
sec. butylamino-theophylline;
7-{3-[2-(3,5-dihodroxyphenyl)-2-hydroxyethyl-amino]-propyl}-8-phenethyl-th
eophylline;
7-{3-[2-(3,4-dihydroxyphenyl)-2-hydroxyethylamino]-propyl}-8-thiomorpholin
o-theophylline;
7-{3-[2-(3,4-dihydroxyphenyl)-2-hydroxyethylamino]-propyl}-8-piperidino-th
eophylline;
7-{3-[2-(2-hydroxyphenyl)-2-hydroxyethylamino]-propyl}-8-piperazino-theoph
ylline;
7-{3-[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl-amino]-propyl}-8-(2-butyl)
morpholino-theophylline;
7-{3-[2(3,4-dihydroxyphenyl)-2-hydroxyethylamino]-propyl}-8-pyrrolidino-th
eophylline;
7-{3-[2-(3,4-dihydroxylphenyl)-2-hydroxyethylamino]-propyl}-8-azacyclohept
yl-theophylline;
7-{3-[2-(3,5-dihydroxyphenyl)-2-hydroxyethylamino]-propyl-8-(1-oxa-4-azacy
cloheptyl)-theophylline.
The compounds of the invention can be prepared by methods which are
known in themselves. Thus, there can be used the procedures
employed in Klingler U.S. Pat. application Ser. No. 163,468 filed
July 16, 1971, now U.S. Pat. No. 3,728,346 and in Klingler U.S.
Pat. application Ser. No. 284,911 filed Aug. 30, 1972, now U.S.
Pat. 3,855,221 entitled "Hydroxyphenyl Hydroxyethylaminoalkyl
Theophyllines" (corresponding to Austrian application 7745/71 filed
Sept. 6, 1971) by replacing the hydrogen nucleus in the 8-position
of the theophylline nucleus of the starting material of those
applications with the grouping R.sub.4 as defined above. The entire
disclosures of the two above-mentioned Klinger U.S. applications is
hereby incorporated by reference.
Thus, the compounds of the present invention can be prepared by
reacting:
a. a compound of the formula: ##EQU5##
with a compound of the formula: ##EQU6## where Y is oxygen or
hydroxyl plus a hydrogen and X and Y are different one being a
halogen and the other an amino group except that if Z is an amino
group and Y is a hydroxyl group plus hydrogen X can also form an
ethylene oxide ring; if a keto group is present in the compound
obtained, it is reduced to a hydroxyl group;
b. by condensing a compound of the formula: ##EQU7##
with a compound of the formula: ##EQU8## where V and W are always
different and V is the aldehyde group --CHO or the group --CH.sub.2
NH.sub.2 and W is the group --C(R.sub.1)= O or --CH(R.sub.1)= O or
--CH(R.sub.1)--NH.sub.2 and Y is an oxygen atom or a hydroxyl group
plus a hydrogen atom, with simultaneous or subsequent
hydrogenation.
In the above recited processes, it is frequently expedient to
protect the phenolic hydroxyl groups as well as the amino groups by
a known protective group. Frequently such protective groups are
already required for the starting compounds. These protective
groups are easily splittable from the end products. It is either a
matter of easily solvolytic splittable acyl groups or hydrogenating
splittable groups as for example the benzyl group. the solvolytic
splittable protective groups are split off for example by
saponification with dilute acids at room temperature or by a short
boiling. According to the type of protective group, however, the
splitting also takes place during the reaction process. For
example, the latter is the case if the amino group as well as, in a
given case, the phenolic hydroxyl group also are protected by a
benzyl group or a carbobenzoxy group and for example a keto group
is hydrogenated. If the protective group is not split off during
the reaction, a simple after treatment of the reaction product is
necessary wherein then the splitting off of the protective groups
takes place, for example under the conditions given above.
As protective groups for the amino groups there can be used, for
example: the benzyl group, .alpha.-phenylethyl group, benzyl groups
substituted in the benzene nucleus such as, for example, the
p-bromo or p-nitrobenzyl group, the carbobenzoxy group, the
carbobenzthio group, the trifluoroacetyl group, the phthalyl group,
the trityl group, the p-toluenesulfonyl group and similar groups.
These same protective groups can be used for the phenolic hydroxyl
groups; additionally there can be used simple acyl groups as, for
example, the acetyl group.
Process (a) is suitably carried out in a solvent such as alcohols,
e.g., methanol, ethanol, propanol, isopropanol, or butanol,
alcohol-water mixtures, dimethyl formamide, aromatic hydrocarbons
such as benzene, toluene, xylene and other aromatic solvents at
elevated temperatures such as for example 50.degree. to
200.degree.C. In a given case an acid acceptor is employed such as
alkali carbonates, for example, potassium carbonate and sodium
carbonate, tertiary amines, e.g., tributylamine or excess amine
reactant. On occasion the process also can be carried out without a
solvent.
In the case where Y is oxygen, the keto groups in the compound
obtained must be reduced to the hydroxyl group. As catalysts, there
can be used, for example, the customary finely divided metal
catalysts such as noble metal catalysts, for example, platinum and
especially palladium. The reduction can be carried out at normal
temperature or elevated temperature. Suitably there is used a
temperature range of about 40.degree. to 100.degree.C in a solvent
such as lower aliphatic alcohols, e.g., methanol, ethanol,
isopropanol, propanol and butanol, alcohol-water-mixtures dimethyl
formamide, etc. There can be employed the free bases of formula II
or the salts. If the phenolic hydroxyl groups as well as the
secondary amino groups contain benzyl protective groups then these
are split off simultaneously in the catalytic hydrogenation if, for
example, a palladium catalyst is used. The reduction of the keto
group can also take place with the aid of other known reducing
agents which reduce a keto group to the hydroxyl group. These types
of reducing agents are, for example, nascent hydrogen, (for example
zinc-acid such as zinc-glacial acetic acid or zinchydrochloric
acid, aluminum amalgam, metal hydride or complex metal hydrides
(such as LiH, LiAlH.sub.4, alkali borohydrides such as sodium
borohydride or lithium borohydride, sodium-triexthoxyaluminum
hydride), aluminum alcoholates such as aluminum
isopropylate-isopropanol (Meerwein-Ponndorf process), etc.
If R is the hydroxymethyl group under mild conditions, there is
obtained the end product of formula I when R is --CH.sub.2 OH and
by stronger conditions the end product where R is CH.sub.3. If it
is desired to maintain the CH.sub.2 OH group it is suitable to work
at low or only slightly elevated temperatures as well as at normal
pressure and to add the starting compound as the base. Another
possibility is to reduce the ketone with a reducing agent which
only attacks keto groups, especially complex metal hydrides such as
sodium borohydride or lithium aluminum hydride and in a given case
to subsequently split off the protective group by catalytic
hydrogenation under mild conditions. This type of process is
illustrated by example 2 of Klingler application Ser. No. 284,911,
filed Aug. 30, 1972, now U.S. Pat. No. 3,855,221 entitled
"Hydroxyphenyl Hydroxyethylaminoalkyl Theophyllines".
To recover the end product of formula I in which R is CH.sub.3 in
the case that R is CH.sub.2 OH in the starting material of formula
II hydrogenation is carried out until the amount of hydrogen
calculated for the reduction of the keto group and the
hydroxymethyl as well as in a given case for the splitting off of
the protective group is taken up (pH in the acid region and
elevated pressure are favorable for this).
In process (b) there can be used room temperature or elevated
temperature. There can be used normal pressure or elevated
pressure. The raction according to this process is carried out in a
solvent such as alcohols, e.g., methanol, ethanol, isopropanol,
propanol and butanol, water-alcoholmixtures, dimethyl formamide or
dimethyl formamide containing mixture. There can be used the
customary hydrogenation catalysts such as platinum, palladium or
nickel with or without carriers. If hydrogenolytically splittable
protective groups are present on the nitrogen of the side chain or
on the hydroxyl groups of the phenyl radical these are
simultaneously split off by using palladium as the hydrogenation
catalyst.
The reduction step can take place simultaneously with the
condensation or the Schiff's base can be first isolated and this
reduced subsequently.
In processes (a) and (b) there can also be employed starting
materials of formulas II and IV in which R.sub.4 is replaced by an
unsaturated radical such as for example an aliphatic alkenyl group
having 1 to 6 carbon atoms or a phenyl alkenyl group having at
least 8 to 12 carbon atoms. In this case, catalytic hydrogenation
must always be employed whereby the unsaturated residue is
converted to the corresponding saturated radical.
Those compounds which contain asymmetric carbon atoms and which as
a rule are obtained as recemates can be split in known manner, for
example, by means of optically active isomers, into optically
active acid. However, it is also possible from the outset to employ
optically active or disastereometric starting materials whereby
there is obtained as the final product a corresponding pure
optically active form or a disastereomer configuration. There can
also occur stereoisomer racemates since they are present in the
compounds produced two or more asymmetrical carbon atoms.
Separation is possible in the customary manner, for example, by
recrystallization.
As stated previously the compounds of the invention are useful in
the production of pharmaceutical compositions. The pharmaceutical
compositions or medicaments can contain one or more of the
compounds of the invention or mixtures of these with other
pharmaceutically active materials. For the production of
pharmaceutical preparations there can be used the customary
pharmaceutical carriers and assistants. The medicines can be used
enterally, parenterally, orally or perlingually. Dispensing can
take place in the form of tablets, capsules, pills, dragees, plugs,
ointments, powders, liquids or aerosols. As liquids there can be
used oily or aqueous solutions or suspensions, emulsions,
injectable aqueous and oily solutions or suspensions.
Unless otherwise indicated all parts and percentages are by
weight.
Many of the starting theophylline derivatives are known. Those
which are not (as well as those which are) can be obtained by the
following processes:
PROCESS (a)
Compounds of Formula II in which Z is a halogen can be produced by
reacting a compound of the following formula: ##EQU9## with a
1,3-dihalopropane, e.g., 1,3-dichloropropane or 1,3-dibromopropane
with addition of an alkaline agent such as soda lye for example.
The reaction is carried out at 50.degree. to 200.degree.C with
solvents such as water, alcohols, e.g., methanol, ethanol,
isopropanol, propanol or butanol, dimethyl formamide, dioxane or
mixtures of these solvents.
The compounds of Formula II where Z is NH.sub.2 or, for example a
benzylamino group are prepared from the corresponding halo
compounds by reaction with excess ammonia in an autoclave at a
temperature between 80.degree. and 150.degree.C or by reaction with
benzylamine without pressure in the same temperature range. As
solvents there can be used water, alcohols, e.g., methanol,
ethanol, isopropanol, propanol or butanol, water-alcohol-mixtures,
dimethyl formamide, hydrocarbons such as toluene and xylene.
Those starting compounds of Formula II in which X with Y form an
ethylene oxide ring can be produced from the corresponding
halohydrins by reaction with alcoholic KOH at low temperatures.
Phenolic hydroxyl groups are likewise preferably protected. This
general procedure is disclosed in Houben/Weyl Vol. 6/3/ pages 374
et seq.
PROCESS (b)
To produce the aldehydes of Formula IV for example potassium
theophylline substituted in the 8-position by R.sub.4 can be
reacted with .beta.-chloropropionaldehyde diethyl acetal in a
manner analogous to that disclosed in Kohlstaedt German patent is
hereby incorporated by reference.
EXAMPLE 1
7-{3-[2-(3,4-dihydroxyphenyl)-2-hydroxyethylamino]-propyl}-8-diethylamino-t
heophylline ##EQU10##
40.5 grams of 7-(3-benzylamino-propyl)-8-diethylamino-theophylline
were dissolved in 95 ml of 25% ethyl alcohol and there was added by
dropping inside two hours with stirring and introduction of
nitrogen to the mixture of a solution of 9.5 grams of
o-chloroacetyl-pyrocatechol in 48 ml of ethyl alcohol. The mixture
was heated for an additional 2 hours, made up to 800 ml with ethyl
alcohol, acidified with alcoholic hydrochloric acid and filtered
with suction after two days. To purify the product, it was boiled
with ethyl alcohol and after cooling filtered with suction. The
yield of the dried hydrochloride was 24 grams, M.P.
237.degree.-239.degree.C.
Unreacted starting material was easily recovered from the
filtrate.
22.6 grams of the
7-{3-[2-(3,4-dihydroxyphenyl)-2-oxoethyl-benzylamino]-propyl}-8-diethylami
no-theophylline hydrochloride thus obtained were dissolved in a
mixture of 226 ml of distilled water, 300 ml of ethyl alcohol and
200 ml of methanol and hydrogenated at 550.degree.C after addition
of 2.3 grams of 10% palladium-activated carbon catalyst. The
mixture was filtered after the end of the hydrogen take-up and the
solvents distilled off. The residue was boiled under reflux with
ethyl alcohol with stirring in a nitrogen atmosphere, the
crystalline reduction product HCl-salt) filtered off with suction
and dried at 50.degree.C. Yield: 5.7 grams, M.P.
216.degree.-217.degree.C (with decomposition).
Production of the starting material (1)
7-chloropropyl-8-diethylamino-theophylline
57.3 grams of 8-diethylamino-theophylline were boiled with 226
grams of 1-chloro-3-bromopropane in 183 ml of isopropanol and 27 ml
of water at reflux. Inside of 7 hours there were added dropwise
with stirring a solution of 23.3 grams of potassium hydroxide in 87
ml of water. The excess chlorobromopropane was distilled off in a
vacuum, the residue dissolved by addition of chloroform and dilute
caustic potash solution, the two layers separated and the
chloroform phase shaken twice with 5% caustic potash and finally
with water.
In a given case the process can be carried out as follows:
The mixture was strongly concentrated in a vacuum. After addition
of 100 ml of chloroform, it was stirred a short time, filtered, the
chloroform phase separated and this phase shaken with 5% caustic
potash. The chloroform solution was dried with potassium carbonate,
the chloroform distilled off and the residue recrystallized from
methanol. There were obtained 47.4 grams of 7-chloropropyl-8
-diethylamino-theophylline having a melting point of
129.degree.-131.degree.C.
2. 7-(3-benzylaminopropyl)-8-diethylamino-theophylline
24 grams of 7-chloropropyl-8-diethylamino-theophylline were
dissolved in 57 ml of toluene and this solution boiled at reflux
together with 14.7 grams of benzylamine and 15 grams of potassium
carbonate with stirring for two days. Then the product was treated
with water and stirred until the inorganic salts were dissolved.
The separate toluene phase was evaporated in a vacuum, the residue
washed well with water and the reaction product brought to
crystallization by stirring with petroleum ether. The melting point
was 73.degree.-77.degree.C.
EXAMPLE 2
7-{3-[1-methyl-2-hydroxy-2-(4-hydroxyphenyl)-ethylamino]-propyl}-8-morpholi
no-theophylline ##EQU11##
33.3 grams of 7-(3-benzylaminopropyl)-8-morpholinotheophylline
together with 12.8 grams of p-benzyloxy-.alpha.-bromopropiophenone
in 120 ml of xylene were boiled at reflux with stirring for 8
hours. Suction filtering was then employed and the filtrate
evaporated in a vacuum. The residue was dissolved in hot ethanol,
filtered and acidified with alcoholic hydrochloric acid. After the
reaction mixture had stood for two days in the refrigerator, it was
filtered with suction and dried at 80.degree.C. There were obtained
23 grams of
7-{3-[1-methyl-2-oxo-2-(4-benzyloxyphenyl)-ethyl-benzylamino]-propyl}-8-mo
rpholino-theophylline hydrochloride having a melting point of
204.degree. to 205.degree.C.
10 grams of the thus recovered material were dissolved in 200 ml of
ethanol and after the addition of 1.0 gram of 5%
palladium-activated carbon catalyst hydrogenated at 60.degree.C.
The product was filtered, evaporated and the residue recrystallized
from ethanol. There were obtained 5.8 grams of the hydrochloride
having a melting point of 220.degree.-221.degree.C.
EXAMPLE 3
7-{3-[2-(3,5-dihydroxyphenyl)-2-hydroxyethylamino]-propyl}-8-morpholiono-th
eophylline ##EQU12##
12.8 grams of 7-(3-aminopropyl)-8-morpholino-theophylline were
caused to react with 7.5 grams of
2-(3,5-dibenzyloxyphenyl)-2-hydroxyethyl bromide in the molten
condition for 5 hours at 135.degree.C with stirring. The reaction
product was heated with toluene, filtered with suction and stirred
with a little water, again filtered with suction and dried at
80.degree.C. By solution in alcohol and acidification with
alcoholic hydrochloric acid there were obtained 3.6 grams of
7-{3-[2-(3,5-dibenzyloxyphenyl)-2-hydroxyethyl-amino]-propyl-
8-morpholino-theophylline hydrochloride, that was purified by
recrystallization from aqueous ethanol, M.P.
199.degree.-203.degree.C.
15 grams of the intermediate product recovered in this manner were
dissolved in 300 ml of ethanol and 60 ml of distilled water and
after addition of 1.5 grams of 5% palladiumactivated carbon
catalyst hydrogenated at 60.degree.C. The product was filtered,
evaporated and the residue heated with ethanol whereupon the
hydrochloride crystallized out. Yield: 10.4 grams; M.P.
253.degree.-256.degree.C.
Production of the starting material 8-morpholinotheophylline was
reacted with 1-chloro-3-bromopropane in the process described in
example 1 and the compound obtained (M.P. 151.degree.-153.degree.C,
likewise as described in example converted with benzylamine into
the 7-(3-benzylaminopropyl)-8-morpholinotheophylline (melting point
of the hydrochloride 243.degree.-245.degree.C). From this there
were obtained the 7-(3-aminopropyl)-8-morpholinotheophylline (M.P.
90.degree.-93.degree.C) by catalytic hydrogenation in alcoholic
solution at 60.degree.C with use of palladium-activated carbon.
Further examples are given in Table 1 below. The production of
compounds 4 to 10 was carried out in a manner analogous to example
1 and the compounds of examples 11-13 were produced in a manner
analogous to example 3. In table 2 there are given the melting
points of the starting materials for examples 4-8. It may be noted
that the melting points of the two starting materials which were
not given in example 2 are the same as those in example 7. In Table
3 are given the melting points of those intermediate compounds for
making compounds 9 to 13 which are new.
TABLE 1 ______________________________________ COMPOUND OF FORMULA
I EXAMPLE M.P..degree.C. NO. R.sub.1 R.sub.4 Hydrochloride
______________________________________ 4 H --CH.sub.2 --C.sub.6
H.sub.5 115 5 H --(CH.sub.2).sub.3.sup.. CH.sub.3 193-194 6 H
210-211 7 H 195-196 (decomposition) 8 H 188- 189 (decomposition) 9
H 197-198.degree. 10 H 201-204.degree. C.sub.2 H.sub.5 11 H
--N.angle. 277-278.degree. C.sub.2 H.sub.5 12 H 261-262.degree. 13
H 208-210.degree. ______________________________________
TABLE 2
__________________________________________________________________________
MELTING POINT .degree.C of Intermediates INTERMEDIATES
--N--CH.sub.2 --CO FOR COMPOUND OF CH.sub.2 C.sub.6 H.sub.5
__________________________________________________________________________
EXAMPLE 4 R.sub.4 =CH.sub.2 --C.sub.6 H.sub.5 130 - 132.degree.C
179 - 185.degree.C 180 - 184.degree.C R.sub.2 R.sub.3 =3,4--OH
(Hydrochloride) (Hydrochloride) EXAMPLE 5 R.sub.4 =C.sub.4 H.sub.9
124 - 125.degree.C 232 - 234.degree.C 150 - 155.degree.C R.sub.2
R.sub.3 =3,4--OH (from Methanol) (Hydrochloride) (Hydrochloride)
EXAMPLE 6 R.sub.4 = 126 - 130.degree.C 90 - 98.degree.C 166 -
172.degree.C (Hydrochloride) R.sub.2 R.sub.3 =3,4--OH EXAMPLE 7
R.sub.4 = 151 - 153.degree.C 243 - 245.degree.C Methanol 246 -
247.degree.C (Hydrochloride) (Hydrochloride) R.sub.2 R.sub.3
=3,4--OH EXAMPLE 8 R.sub.4 = 121 - 123.degree.C 113 - 115.degree.C
from Methanol 218 - 220.degree.C (free base) (Hydrochloride)
R.sub.2 R.sub.3 =3,4--OH
__________________________________________________________________________
TABLE 3
__________________________________________________________________________
MELTING POINT .degree.C. of Intermediates (CH.sub.2).sub.3
--NH--CH.sub.2 --CH (CH.sub.2).sub.3 --N--CH.s ub.2 CO
INTERMEDIATES .vertline. .vertline. FOR COMPOUND OF OH CH.sub.2
C.sub.6 H.sub.5
__________________________________________________________________________
EXAMPLE 9 known no intermediate of this type 172-176.degree.C
90-93.degree.C (Hydrochloride) (free base) EXAMPLE 10 known no
intermediate of this type 199-202.degree.C 90-93.degree.C
(Hydrochloride) (free base) EXAMPLE 11 87-89.degree.C
166-168.degree.C no intermediate of (free base) (Hydrochloride)
this type EXAMPLE 12 235-237.degree.C 193-197.degree.C no
intermediate of (Hydrochloride) (Hydrochloride) this type EXAMPLE
13 100-102.degree.C 208-209.degree.C no intermediate (free base)
(Hydrochloride) of this type
__________________________________________________________________________
The compounds of the invention are suited for the production of
pharmaceutical compositions and preparations. The pharmaceutical
compositions or drugs contain as the active material one or several
of the compounds of the invention, in a given case in admixture
with other pharmacologically or pharmaceutically effective
materials. The production of the medicine can take place with the
use of known and customary pharmaceutical carriers and diluents, as
well as other customary assistants.
Such carriers and assistants are set forth for example in Ullmann's
Encyklopadie der technischen Chemie, Vol. 4 (1953), pages 1 to 39;
Journal of Pharmaceutical Sciences, Vol. 52 (1963), pages 918 et
seq; Hiv. Czetsch-Lindenwald, Hilfstoffe fur Pharmazie und
angrenzende Gebiete; as well as in Pharm. I Vol. 2 (1961) pages 72
et seq.
Examples of such materials include gelatin, sucrose, pectin,
starch, tylose, talc, lycopodium, silica, lactose, cellulose
derivatives, micropulverized cellulose, stearates, e.g.,
methylstearate and glyceryl stearate, emulsifiers, vegetable oils,
water, pharmaceutically compatible mono- or polyvalent alcohols and
polyglycols such as glycerine, mannitol, sorbitol, pentaerythritol,
ethyl alcohol, diethylene glycol, triethylene glycol, ethylene
glycol, propylene glycol, dipropylene glycol, polyethylene glycol
400, as well as derivatives of such alcohols and polyglycols,
dimethyl sulfoxide, esters of saturated and unsaturated fatty acids
with mono- or polyvalent alcohols such as glycols, glycerine,
diethylene glycol, perthaerythritol, sorbitol, mannitol, etc.,
e.g., glyceryl stearate, glyceryl palmitate, glyceryl oleate,
ethylene glycol stearate; such esters of polyvalent alcohols can in
a given case also be etherified, benzyl benzoate, dioxolane,
glycerine formal, glcyol furfural, dimethyl acetamide, lactamide,
lactates, e.g., ethyl lactate, ethyl carbonate, etc.
Furthermore, there can be added preservatives, stabilizers,
buffers, taste correctives, antioxidants and complex formers (for
example ethylenediaminotetraacetic acid) and the like.
As antioxidants there can be used for example sodium metal
bisulfite and ascorbic acid, as preservatives there can be used for
example sorbic acid, p-hydroxybenzoic acid esters, e.g., methyl
p-hydroxybenzoate and ethyl p-hydroxybenzoate and similar
materials.
The pharmacological and galenical treatment of the compounds of the
invention takes place according to the usual standard methods.
The drugs can be used enterally, parenterally, orally, perlingually
or in the form of sprays.
The addition of other medicinally active materials is also
possible.
The compounds of the invention have a good bronchospasmolytic
activity as exhibited, for example, on the isolated tracheal spiral
of the guinea pig.
The bronchospasmolytic activity is comparable to that of the known
drug orciprenaline.
The middle of the bronchospasm at 50-100% expectorant dosage in the
above animal experiments expressed as ED50, for example, at
10.sup..sup.-7 to 10.sup..sup.-9 gram/ml.
The compounds of the invention have utility in treating bronchial
asthma, chronic asthmatic bronchitis, emphysema bronchitis with
spasmic components and additional respiratory illnesses.
The compounds can be delivered in the form of tablets, capsules,
pills, dragees, liquids or aerosols. As liquids there can be used
oily or aqueous solutions or suspensions, emulsions, injectable
aqueous or oily solutions or suspensions. The preferred forms of
use are tablets which contain between 1 and 50 mg. of active
material or solutions which contain between 0.1 and 5% of active
material.
In individual doses the amount of active component of the invention
can be used for example in an amount of 2 mg dispensed orally or 10
strokes of a 0.2% solution dispensed as an aerosol. These doses can
be dispensed once or several times a day.
For example there is recommended the use of 1 tablet containing 2
mg of active ingredients 3 times daily or dispensed as an aerosol 1
to 4 times a day up to 10 strokes of the 0.2% solution.
The acute toxicity of the compounds of the invention in the mouse
(expressed by the LD 50 mg/kg method of Miller and Tainer, Proc.
Soc. Exph. Biol. and Med., Vol. 57 (1944) pages 261 et seq.) in
i.v. application is between 80 mg/kg and 150 mg/kg.
The drugs can be used in human medicine or in veterinary medicine,
e.g., to treat cats, dogs, horses, sheep, cattle, goats and
pigs.
* * * * *